What one share of Arcus Biosciences holds
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs.
Arcus Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.98 |
|---|---|
| Profit | −$3.87 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.99 |
| Cash and investments | $1.18 |
| Debt | $0.80 |
| Book value | $3.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$20.80 | $4.74 | −$19.73 | — | — |
| 2017 | $0.77 | −$29.03 | $3.02 | −$16.72 | — | — |
| 2018 | $0.24 | −$1.43 | $0.11 | −$1.35 | — | $5.28 |
| 2019 | $0.34 | −$1.93 | $0.04 | −$1.72 | — | $3.57 |
| 2020 | $1.42 | −$2.24 | $0.05 | $1.97 | — | $7.71 |
| 2021 | $5.18 | $0.72 | $0.35 | −$3.81 | — | $11.89 |
| 2022 | $1.56 | −$3.71 | $0.08 | $6.00 | — | $9.01 |
| 2023 | $1.58 | −$4.15 | $0.32 | −$4.46 | — | $6.12 |
| 2024 | $2.86 | −$3.14 | $0.07 | −$1.95 | — | $5.26 |
| 2025 | $2.30 | −$3.29 | $0.02 | −$4.51 | — | $5.04 |
Common questions about Arcus Biosciences
How much does one share of Arcus Biosciences earn?
Over the last 12 months, Arcus Biosciences lost $3.87 for each share on $0.98 of sales.
Does Arcus Biosciences pay a dividend?
Arcus Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Arcus Biosciences’s book value per share?
Arcus Biosciences’s book value is $3.65 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Arcus Biosciences have?
Each share of Arcus Biosciences has $1.18 of cash and investments and $0.80 of debt, as of June 30, 2026.
What is Arcus Biosciences’s free cash flow per share?
−$3.99 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Arcus Biosciences bought back shares?
Arcus Biosciences’s share count rose about 12331% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.